ID   U3117MG
AC   CVCL_IS00
SY   U3117-MG; U3117
DR   cancercelllines; CVCL_IS00
DR   GEO; GSM1857610
DR   GEO; GSM1857826
DR   GEO; GSM2368450
DR   GEO; GSM2368607
DR   Progenetix; CVCL_IS00
DR   Wikidata; Q54973731
RX   PubMed=26629530;
RX   PubMed=27689322;
RX   PubMed=27974212;
RX   PubMed=28122246;
WW   http://www.hgcc.se/
CC   Part of: Human Glioblastoma Cell Culture (HGCC) resource.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): PubMed=27974212
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 11,13
ST   D18S51: 13,14
ST   D19S433: 12,14
ST   D21S11: 29,30
ST   D2S1338: 19,25
ST   D3S1358: 16,18
ST   D5S818: 12,14
ST   D7S820: 11
ST   D8S1179: 12,14
ST   FGA: 21,22
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_IS01 ! U3118MG
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 8
//
RX   PubMed=26629530; DOI=10.1016/j.ebiom.2015.08.026;
RA   Xie Y., Bergstrom T., Jiang Y.-W., Johansson P., Marinescu V.D.,
RA   Lindberg N., Segerman A., Wicher G., Niklasson M., Baskaran S.,
RA   Sreedharan S., Everlien I., Kastemar M., Hermansson A., Elfineh L.,
RA   Libard S., Holland E.C., Hesselager G., Alafuzoff I., Westermark B.,
RA   Nelander S., Forsberg-Nilsson K., Uhrbom L.;
RT   "The Human Glioblastoma Cell Culture resource: validated cell models
RT   representing all molecular subtypes.";
RL   EBioMedicine 2:1351-1363(2015).
//
RX   PubMed=27689322; DOI=10.18632/oncotarget.12298;
RA   Schmidt L., Baskaran S., Johansson P., Padhan N., Matuszewski D.J.,
RA   Green L.C., Elfineh L., Wee S.-M., Haggblad M., Martens U.,
RA   Westermark B., Forsberg-Nilsson K., Uhrbom L., Claesson-Welsh L.,
RA   Andang M., Sintorn I.-M., Lundgren B., Lonnstedt I., Krona C.,
RA   Nelander S.;
RT   "Case-specific potentiation of glioblastoma drugs by pterostilbene.";
RL   Oncotarget 7:73200-73215(2016).
//
RX   PubMed=27974212; DOI=10.1016/j.celrep.2016.11.056;
RA   Segerman A., Niklasson M., Haglund C., Bergstrom T., Jarvius M.,
RA   Xie Y., Westermark A., Sonmez D., Hermansson A., Kastemar M.,
RA   Naimaie-Ali Z., Nyberg F., Berglund M., Sundstrom M., Hesselager G.,
RA   Uhrbom L., Gustafsson M., Larsson R., Fryknas M., Segerman B.,
RA   Westermark B.;
RT   "Clonal variation in drug and radiation response among
RT   glioma-initiating cells is linked to proneural-mesenchymal
RT   transition.";
RL   Cell Rep. 17:2994-3009(2016).
//
RX   PubMed=28122246; DOI=10.1016/j.celrep.2017.01.003;
RA   Jiang Y.-W., Marinescu V.D., Xie Y., Jarvius M., Maturi N.P.,
RA   Haglund C., Olofsson S., Lindberg N., Olofsson T., Leijonmarck C.,
RA   Hesselager G., Alafuzoff I., Fryknas M., Larsson R., Nelander S.,
RA   Uhrbom L.;
RT   "Glioblastoma cell malignancy and drug sensitivity are affected by the
RT   cell of origin.";
RL   Cell Rep. 18:977-990(2017).
//